CSPG4 Protein as a New Target for the Antibody-Based Immunotherapy of Triple-Negative Breast Cancer

BACKGROUND: The cell surface proteoglycan, chondroitin sulfate proteoglycan 4 (CSPG4), is a potential target for monoclonal antibody (mAb)–based immunotherapy for many types of cancer. The lack of effective therapy for triple-negative breast cancer (TNBC) prompted us to examine whether CSPG4 is expr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Wang, Xinhui, Osada, Takuya, Wang, Yangyang, Yu, Ling, Sakakura, Koichi, Katayama, Akihiro, McCarthy, James B., Brufsky, Adam, Chivukula, Mamatha, Khoury, Thaer, Hsu, David S., Barry, William T., Lyerly, H. Kim, Clay, Timothy M., Ferrone, Soldano
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2010
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2950168/
https://ncbi.nlm.nih.gov/pubmed/20852124
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djq343
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados